The rate for the latter half of the year brings the full-year average to 23.4% – rising to 24.3% next year and 26% in 2027 – ...

The pressure to execute a flawless drug or therapy launch has never been greater and continues to lay the foundation for long ...

BMS kickstarted its radiopharma drive last year when it completed a $4.1 billion acquisition of San Diego-based RayzeBio, ...

If that sounds like the storyline to Marvel's latest superhero tale, that's because it is. The publisher's latest custom ...

SpliceBio's lead in-house pipeline project is in Stargardt disease, an IRD with no approved therapies that is caused by ...

Makary and Prasad also repeat various themes repeatedly visited by Kennedy on his Make America Healthy Again (MAHA) soapbox, ...

At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.

Adaptive trials allow for modifications to be made during the trial without requiring additional approvals. According to the ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

UK start-up George Medicines has brought its triple therapy for high blood pressure over the finish line, with an FDA ...

AbbVie presented new data from its novel antibody-drug conjugates (ADCs) at ASCO 2025, including telisotuzumab adizutecan ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...